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Class I histone deacetylases (HDACs) are cellular enzymes expressed in many tissues and play crucial roles in diﬀerentiation,
proliferation,and cancer. HDAC1 and HDAC2 in particular are highlyhomologousproteins thatshow redundant or speciﬁc roles
in diﬀerent cell types or in response to diﬀerent stimuli and signaling pathways. The molecular details of this dual regulation are
largelyunknown.HDAC1andHDAC2arenotonlyproteinmodiﬁers,butareinturnregulated bypost-translationalmodiﬁcations
(PTMs):phosphorylation,acetylation,ubiquitination,SUMOylation,nitrosylation,andcarbonylation.SomeofthesePTMsoccur
andcrosstalk speciﬁcally onHDAC1 or HDAC2, creating a rational“code” for a diﬀerential, context-related regulation. The global
comprehension of this PTM code is central for dissecting the role of single HDAC1 and HDAC2 in physiology and pathology.
1.Histone Deacetylases:A NumerousFamily
withMany Biological Roles
Histone deacetylases (HDACs) are modiﬁcation enzymes
that catalyze the removal of acetyl molecules from ε-NH3
groups of lysines, balancing the action of another family of
enzymes, histone acetyl-transferases (HATs), which instead
add acetyl groups.
They were ﬁrst identiﬁed for deacetylating histones
during chromatin remodeling, but many other nonhistone
substrates have been characterized so far: transcription
factors (p53 and Rb proteins), metabolic enzymes (Pyruvate
kinase and Acetyl-CoA syntase), structural proteins (α-
tubulin), enzymes involved in DNA dynamics (PCNA),
as well as exogenous viral proteins (SV40 T antigen or
HIV integrase) [1]. It is now clear that acetylation is a
cellular broad-spectrum regulatory mechanism and HDACs
are thought to be general deacetylation enzymes: in fact, it
wasrecently proposedto rename themmore properly “lysine
deacetylases” (K[Lys]DAC) [2]. Nevertheless, since the name
HDACs has historically entered into the acetylation ﬁeld,
in this paper we will refer to them as histone deacetylases
(HDACs).
Histone deacetylases constitute an ancient enzyme fam-
ily, conserved in evolution from yeast to plants and animals
[3]. HDAC-like proteins are found as well in Eubacteria and
Archaebacteria [4].
In humans, 18 HDACs have been described so far,
divided into two families according to their mechanism of
catalysis: zinc and NAD+ dependent.
The zinc-dependent HDACs belong to the classical
Rpd3/Hda1 family, while the NAD+-dependent HDACs
belong to the Sirtuin family.
Another complementary criterion of classiﬁcation is
based on sequence homology to the corresponding Saccha-
romyces cerevisiae proteins. According to this classiﬁcation,
HDACs are divided into four classes.
ClassIHDACs(HDAC1,HDAC2,HDAC3,andHDAC8)
are homologous to the yeast RPD3 protein. Class II includes
HDACs homologous to the yeast HDA1 protein, and is fur-
ther divided into two subclasses: class IIa (HDAC4, HDAC5,
HDAC7, and HDAC9) and class IIb (HDAC6 and HDAC10)
[5]. Class III corresponds to the NAD+-dependent Sirtuin2 Journal of Biomedicine and Biotechnology
family and is composed of seven members, Sirt1-7 [6].
HDAC11 is the only member identiﬁed so far belonging to
class IV; it is a zinc-dependent deacetylase sharing common
features with both class I and class II HDACs [7].
The multiplicity of histone deacetylases reﬂects a diver-
siﬁcation of functions in diﬀerent tissues and biological
processes. Sirtuins are mainly involved in metabolism and
aging [6]; HDAC11 was shown to regulate the balance
between immune activation and immune tolerance in CD4+
T-cell [8] and plays a role in oligodendrocyte diﬀerentiation
[9].
Class II members have a variety of diﬀerent roles in mus-
cle, heart, and bone development and physiology, and they
are expressed with a certain grade of tissue speciﬁcity [10].
Class II HDAC6 is the main cytosolic deacetylase controlling
the cytoskeleton dynamics and chaperone functions through
acetylation of α-tubulin and HSP90, respectively [11, 12].
On the contrary, class I HDACs are ubiquitously
expressed in all tissue types [10]. HDAC8 plays an important
role in smooth muscle cells, where it associates with α-
actin and is essential for cell contractility [13]. Recently, a
relation between HDAC8 transcriptional overexpression and
advanced ormetastasized stagesofchildhood neuroblastoma
was described [14].
HDAC3 has a role in cell cycle progression and DNA
damage response [15], as well as in spindle assembly
checkpoint and sister chromatid cohesion [16]. Germline
deletion of HDAC3 is lethal and embryos die before day
9.5, while conditional knockout of HDAC3 in MEF cells
aﬀects the transcription of a variety of genes involved in
metabolism, cell cycle, apoptosis, development, and signal
transduction [15]. Liver-speciﬁc knockout of HDAC3 leads
to hypertrophy of hepatocytes and dysregulation of lipid
metabolism [17].
HDAC1 and HDAC2, which are strictly related proteins,
also have crucial roles in development and physiology,
especially in the heart and nervous system [18]. They are
also deeply involved in cellular proliferation, cell cycle,
and apoptosis. HDAC1 has a pivotal role in the regulation
of the cyclin-dependent kinase inhibitor p21 [19], and
knockout mice for HDAC1 are embryonic lethal due to a
strong impairment in cellular proliferation [20]. Depletion
of HDAC1 results in perturbation of the cell cycle with loss
of mitotic cells and increase in cell death in diﬀerent human
cancer cell lines [21]. In this paper, we will describe in detail
the regulation of class I HDACs, and in particular of HDAC1
and HDAC2.
2.RegulationofClassIHDACs
The activity ofclassIHDACsin the cellsisregulated through
three main mechanisms: subcellular localization, association
with other proteins into multisubunit complexes, and post-
translational modiﬁcations (PTMs).
Class I HDACs are thought to be for the most part
nuclear, with the exception of HDAC3, which possesses a
nuclear export signal and can be found also in the cytoplasm
[22, 23]. HDAC1, HDAC2, and HDAC3 are usually localized
on chromatin, except during mitosis when all the three
HDACs are excluded from compact, mitotic chromosomes
[15,24].Themoleculardetailsofhowthisexclusionisdriven
are still unknown.
HDAC1 and HDAC2, together with the histone binding
proteins RbAP46 and RbAP48, are part of the catalytic
core of many multiprotein transcriptional complexes, and
this association stimulates their enzymatic activity [25]. The
Sin3aand theNuRDcomplexesare broad-actionmodulators
of gene transcription [26, 27] and bind a spectrum of
diﬀerent cofactors such as Sds3 [25]a n dS A Pp r o t e i n s[ 28],
and Mi2, MTA2, and MBD3 [29], respectively. On the
other hand, the REST/CoREST complex has more speciﬁc
functions: it recruits HDAC1 and HDAC2 to suppress the
transcription of neural genes in non-neural tissues [30, 31].
Recently, two other HDAC1/HDAC2 containing com-
plexes were characterized; the SHIP and the NODE com-
plexes.SHIP1isaDNA-remodelingproteininvolvedinchro-
matin dynamics during spermatogenesis: mass spectrometry
analysis identiﬁed HDAC1 (but not HDAC2) as one of the
components of the SHIP1 complexes [32].
NODE complex is peculiar of embryonic stem (ES) cells:
HDAC1/HDAC2 containing complexes associate with the
ES-speciﬁc transcription factors Nanog and Oct4, switching
oﬀ speciﬁc target genes, and thus determining stem cell fate
[33]. HDAC1/HDAC2 complexes are functionally distinct
from HDAC3-containing complexes, such as the SMRT/N-
CoR complex [34], thus suggesting a diﬀerentiation of
biological roles between HDAC1/HDAC2 and HDAC3. To
date, HDAC8 has not been reported to associate in macro-
molecular complexes.
HDAC1 and HDAC2 are not only protein-modiﬁers, but
they are in theirturn widely post-translationally modiﬁed, as
it will be exhaustively described in the following paragraphs.
Post-translational modiﬁcations (PTMs)representaversatile
and rapid mechanism to modulate protein functions and
properties, such as enzymatic activity, subcellular localiza-
tion, stability, and interaction with other binding partners in
response to diﬀerent extra- or intracellular stimuli. They can
be either chemical moieties (acetylations, phosphorylations,
methylations, nitrosylations, ADP-ribosylations, glycosyla-
tions, and carbonylations) [35] or proteins (ubiquitin,
SUMO, NEDD8, FAT10, ISG15, and Atg8/Atg12)[36].
It is possible that the key to dissect single-HDAC-
speciﬁc functions lies in decoding their PTM code, also,
considering that, as it will be shown below, PTMs actively
inﬂuence HDACs subcellular localization, enzymatic activity
and complexformation. Giventheaboveconsiderations,and
given the strong association between HDAC1 and HDAC2
deregulation with the onset of many human diseases (from
cancer to neuronal disorders, diabetes, and airway diseases),
in this paper we will attempt to give a global overview of the
post-translational code of HDAC1 and HDAC2.
3.HDAC1 and HDAC2:EqualbutNot
Too Much?
HDAC1 and HDAC2 are two highly related proteins, which
are the result of the duplication of an ancient gene [5]. TheyJournal of Biomedicine and Biotechnology 3
share 85% of global sequence identity, but this identity is
not uniformly distributed; the dimerization and catalytic
domains, which comprise the N-terminal two thirds of
the proteins (amino acids 1-325), are 92% identical, while
the C-terminal domains share 72% of identity. Even if
the C-terminal domain has no catalytic activity per se,i t s
deletion greatly reduces HDAC1 enzymatic activity [26],
indicating that it plays an important role in the regulation
of its functions. HDAC1 and HDAC2 are not only highly
related in their structure and share many binding partners
in macromolecular complexes (see above), but they have
also redundant roles in a variety of biological processes.
Conditional deletion of HDAC1 or HDAC2 was tolerated
in diﬀerent organs, such as the heart and the brain, if at
least one allele of HDAC1 or HDAC2 was maintained [37],
while concomitant deletion of both HDAC1 and HDAC2
caused mitotic catastrophe and cell death [38]. Diﬀeren-
tiation of neuronal precursors into neurons requires the
presence of either HDAC1 or HDAC2, strongly suggesting a
compensatory eﬀect [39]. Consistent with this observation,
depletion of either HDAC1 or HDAC2 by RNA interference
in cancer cell lines causes a compensatory upregulation
of HDAC2 or HDAC1, respectively [21]. The redundancy
of HDAC1 and HDAC2 has also been observed in the
hematopoietic system. Levels and activities of HDAC1 and
HDAC2 are critical for erythrocytic and megakaryocytic
diﬀerentiation, and inactivation of HDAC1 and HDAC2
togetherresults in severe thrombocytopeniadue to apoptosis
of megakaryocytes [40].
Nevertheless, the global picture is far more complex,
because in other physiological settings HDAC1 and HDAC2
have speciﬁc and not compensatory functions. For example,
knockout mice for HDAC1 die early in embryogenesis
at E 9.5 [20], while knockout mice for HDAC2 survive
until the perinatal period [37]. It was reported that in
HeLa cervical cancer cells RNA interference for HDAC2
results in an increase in p21CIP/Waf1 expression [41], while
in other cell types, like osteosarcoma U2OS cancer cells,
p21CIP/Waf1 is upregulated also after HDAC1 depletion [21].
Finally,HDAC1,butnotHDAC2,controlsESdiﬀerentiation.
Speciﬁc depletion of HDAC1 results in decrease activity of
Sin3A, NuRD, and CoREST complexes, with concomitant
decrease in acetylation of K56 of histone H3. Moreover,
embryoid bodies derived from HDAC1-deprived (but not
HDAC2-deprived) ES showed altered patterns of cardiomy-
ocyte and neuronal markers [42].
The molecular rationale of when and why HDAC1
and HDAC2 have overlapping versus speciﬁc functions in
diﬀerent contexts is not yet clear. It is likely dependent on
the cell or tissue types expressing speciﬁc combinations of
proteins that can associate speciﬁcally with HDAC1 and
HDAC2 or expressing diﬀerent signaling pathways, in which
PTMs likely act as principal eﬀectors. It will be challenging
to investigate whether a ﬁne-tuned, diﬀerential PTM code
might orchestrate diﬀerential functions of HDAC1 and
HDAC2, thus creating a “single-HDAC regulatory code”
despite their high overall similarity.
4.The Post-Translational Modiﬁcation Code of
HDAC1 and HDAC2
HDAC1 and HDAC2 are subjected to both chemical and
protein PTMs. Although some PTMs occur in the catalytic
domain, the majority of them occur in the less conserved C-
terminal domain part (see Figures 1(a) and 1(b)). Known
PTMs and their biological eﬀects on HDAC1 and HDAC2
will be analyzed and compared.
4.1. Phosphorylation. Among the various post-translational
modiﬁcations that occur on HDAC1 and HDAC2, phospho-
rylation is the best studied.
Phosphorylation in eukaryotesconsistsofthe addition of
a phosphate group (PO4) on serine, threonine, or tyrosine
residues by speciﬁc enzymes deﬁned kinases. Phosphatases
instead remove phosphate groups from proteins, balancing
the action of the kinases [44].
HDAC1 is a substrate in vitro for phosphorylation by
casein kinase II (CKII) and PKA but not by PKC, Cdc2, or
MAP kinases [45].HDAC2is also phosphorylated byCKIIin
vitro, but unlike HDAC1, it is not a substrate for PKA [46].
The main kinase responsible in vivo for HDAC1 and
HDAC2 phosphorylation is casein kinase II (CKII), which
is also found in the HDAC1/HDAC2 containing complexes
such as Sin3 and NuRD complexes [47]. It phosphorylates
HDAC1 on serines 421 and 423, and mutations in these sites
determine reduction of deacetylating and transcriptional
repression activities and interaction with RbAP48, Sin3a,
CoREST, and MTA-2 [48].
It was also reported that CKII-dependent phosphoryla-
tion on HDAC1 is constitutive throughout the cell cycle, but
dispensable for its intrinsic activity in vitro [49]. This was
also conﬁrmed in another study where HDAC1 treated with
calf intestinal phosphatase is still abletodeacetylatea histone
H4-derived peptide [45]. An additional phosphorylation
site on tyrosine 221 HDAC1 was discovered through mass
spectrometry screenings [46]: it is the only example of
tyrosine phosphorylation on HDAC1, but without any
evident role yet.
CKII also widely phosphorylates HDAC2 in vitro and
in vivo on serines 422 and 424, homologues of HDAC1
CKII-sites, and on serine 394, which seems to be the main
phosphorylation site for HDAC2 [50]. Interestingly, one
phosphorylation site was found in the region 386–409 of
HDAC1 [45] and recent high throughput mass spectrometry
analysis has identiﬁed the correspondent serine 393 of
HDAC1 as a new phosphorylation site, but the role is still
to be deﬁned [51].
ItwasalsoreportedforHDAC2afourthphosphorylation
site on serine 411, but it seems to be independent from CKII
action and its role is still unknown. In analogy with HDAC1,
HDAC2 catalytic activity as well as the binding with Sin3a
and Mi2 is promoted by CKII-dependent phosphorylation,
while it does not aﬀect the binding of HDAC2 with
HDAC1 [50]. This is consistent with a previous study, which
identiﬁed the interaction domain of HDAC1with HDAC2in
the N-terminal region of HDAC1 [43].4 Journal of Biomedicine and Biotechnology
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Figure 1: Schematic representation of the PTMs spatial distribution of HDAC1 and HDAC2. (a) Organization of the functional domains
of HDAC1 and HDAC2, as described in [43]. Numbers indicate the corresponding amino acidic (aa) positions.Percentages of identity were
calculated by BLAST alignment of HDAC1 (CAG46518.1) and HDAC2 (AAH31055.2) protein sequences. (b) and (c) Visual comparison
of the diﬀerent PTMs occurring on HDAC1 and HDAC2 in the C-terminal (B) and central (C) domains. Diﬀerent PTMs are illustrated by
diﬀerent colorsand letters: P (yellow):phosphorylation,A (green):acetylation, U (blue):ubiquitination,S (red): SUMOylation,N (orange):
nitrosylation,andC(lilac):carbonylation.Theaminoacidicsites ofmodiﬁcationareindicated bythenumber oftheirpositionintheprotein
sequence:S:serine,K:lysine,Y:tyrosine,C:cysteine,andCBP:CBPhistoneacetyltransferase.Whentheprecisepositionofamodiﬁedresidue
isnotknown,theaminoacidicsiteisfollowedbyanx.Thequestionmark(?)isusedwhen theprecise aminoacidicsitehasnotbeen formally
identiﬁed. The amino acids at the boundaries of the two domains are reported.
CKII-driven phosphorylation of HDAC2 has been
reported to regulate its diﬀerential distribution on speciﬁc
functional areas of chromatin. In particular, unmodiﬁed
HDAC2 is associated with coding region of genes con-
tributing to active transcription, while the phosphorylated
population is more involved in gene regulation, being
preferentially recruited to gene promoters by RbAP48 into
Sin3 and NuRD complexes [47, 52].
Phosphorylation ofHDAC2onserine424isalsoinvolved
in the response of vascular smooth muscle cells to stimula-
tion with all-trans retinoic acid (ATRA). Upon stimulation,
a signaling cascade operating via the JNK kinase determines
anincreaseinHDAC2phosphorylation,which inturncauses
the dissociation of HDAC2 from its binding partner KLF4.
The consequent increase in KLF4 acetylation leads to the
expression of diﬀerentiation marker genes such as SM22α
[53].
CKII-dependent phosphorylation of HDAC2 on serines
394, 411, 422, and 424 increases upon exposure to cigarette
smoke (CS) and is related to an increase in ubiquitination
and degradation by the proteasome pathway in macrophage,
human bronchial epithelial and small airways epithelial cells
as well as in the lung of living mice [54]. Interestingly,
single mutations of serine 394 or serine 424 did not
aﬀect global HDAC2 phosphorylation after CS exposure as
the quadruple mutant did, suggesting a certain grade of
redundancy between the sites [55]. Since HDAC2 suppresses
expression of genes involved in inﬂammation, and cigarette
smoke causes oxidative stress and is the primary risk factor
for chronic obstructive pulmonary disease (COPD), theJournal of Biomedicine and Biotechnology 5
elucidation of this mechanism may have clinical relevance
in the steroid resistance observed in COPD patients and in
smokers aﬀected by severe asthma.
The biological relevance of HDAC1 and HDAC2 phos-
phorylation is also depicted by the fact that some viruses
induce their hyperphosphorylation in the early phase of
infection. US3 kinase from human Herpes Simplex Virus
1[ 56] and its homologue ORF66 kinase from Varicella
Zoster Virus [57] both induce, even if indirectly, hyper-
phosphorylation of HDAC1 and HDAC2. The target sites
of ORF66-induced phosphorylation were identiﬁed as serine
406 of HDAC1 and serine 407 of HDAC2 [57]. Recently,
also the nonhuman herpesvirus Pseudorabies Virus (PRV)
US3 kinase was shown to induce phosphorylation ofHDAC2
on serine 407, indicating a conserved eﬀect of many her-
pesviruses on this deacetylase [58]. The kinase(s) directly
responsible for HDAC1 and HDAC2 phosphorylations in
vivoisunknown;CKIIseemsunlikelytobethecellularkinase
involved, since it requires the acidic consensus sequence S/T-
X-X-E [59], not present in the region encompassing serines
406 of HDAC1 and 407 of HDAC2.
CKII-dependent phosphorylation of HDAC1 and
HDAC2 is also increased in response to hypoxic conditions,
and this correlates with an increase in HDAC enzymatic
activity [60]. These studies suggest that phosphorylation is a
key signaling factor of diﬀerent pathways that converge on
HDAC1 and HDAC2 to carry on biological responses.
Finally, it was shown that proper histone deacetylation
is required for meiotic resumption in porcine oocytes, and
phosphorylation of HDAC1 was observed to rapidly change
during oocyte maturation. The role of HDAC1 phosphory-
lation in the meiotic process has not been investigated in
details but it is another indication of the variety of biological
processeswhere phosphorylation ofHDAC1isinvolved[61].
Protein phosphatases are as important as protein kinases
in regulating the phosphorylation status of substrates.
HDAC1 and HDAC2 are dephosphorylated in vitro by pro-
tein phosphatase 1 (PP1) and λ-phosphatase [62]. Treatment
of diﬀerent cell lines with the phosphatase inhibitor okadaic
acid induces the appearance of hyperphosphorylated forms
of HDAC1 and HDAC2, associated with a slightly decrease
in HDAC activity and loss of binding between HDAC1 and
Sin3a and HDAC1/HDAC2 with the transcriptional partner
YY1 [62]. Apparently, this seems in conﬂict with the work
described above showing that phosphorylation positively
regulates HDAC1 and HDAC2 enzymatic activities and
binding properties. It is worth pointing out that the diﬀerent
studies used diﬀerent approaches (site-directed mutagenesis
versus treatment with a general phosphatase inhibitor), and,
considering the complexity of the system of modiﬁcations
acting on HDAC1 and HDAC2, this could at least in part
account for the apparent discrepancy. HDAC1 and HDAC2
interactwithproteinphosphatasesin vivo[63,64];treatment
of cells with the pan HDAC inhibitor trichostatin A (TSA)
[65] causes destruction of a HDAC1-PP1 complex [66,
67], but the catalytically dead mutant of HDAC1 (HDAC1
H141A) still retained binding with PP1 [63]. This example
shows that the use of aspeciﬁc, general inhibitors of the
enzymatic activity of an enzyme (TSA or okadaic acid) may
have diﬀerent eﬀects compared to the use of more speciﬁc
point mutants.
HDAC1, and to a lesser extent HDAC2, were found
in complex with PP1 and the transcription factor CREB.
HDAC1 and PP1 cooperate to deacetylate histones and
to dephosphorylate CREB, thereby silencing CREB-driven
transcription in c-AMP unstimulated cells or in later times
after stimulation, contributing to signal attenuation [63].
HDAC1 and PP1 are also part of a complex with the
Rb protein, which is dissociated in response to ionizing
radiationsinanATM-dependentpathway[68].Inbraincells,
PP1-HDAC1 containing complexes are central actors in the
modulation of the epigenetic histone code at the promoters
of genes implied in memory formation [69].
Although it is likely that many other phosphorylation
sites will be identiﬁed in the future, phosphorylation of
HDAC1 and HDAC2 has been biochemically well character-
ized so far, but a whole comprehension of its biological roles
is still elusive. It is likely that the scenario will become more
and more sophisticated in the future, as long as new PTMs
and the crosstalk between them will be discovered.
4.2. Acetylation. Histone deacetylases are the main actors in
the acetylation network that takes place in cells, but they are
themselves regulated by acetylation.
HDAC1 can be acetylated on six lysines: K218, K220,
K432, K438, K439, and K441. It was shown that in
cells, a subpopulation of HDAC1 is acetylated by the
acetyltransferase p300 at the promoter of glucocorticoid-
receptor (GR) driven genes one hour after binding of the
hormone. Acetylation of HDAC1 reduces dramatically its
enzymatic and repression activities in vitro and in vivo.
H D A C 1a c t sa sac o a c t i v a t o ro fG Ra c t i v a t i o no fp r o m o t e r s ;
consequently, a mechanism was proposed that after gene
activation induced by the hormone, p300 is recruited at the
promoter, and HDAC1 becomes acetylated and inactivated
to allow the attenuation of the signal and the restoration of
the transcriptional steady-state levels [70].
On the contrary, HDAC2 is not acetylated in vitro by
p300 even if ﬁve out of the six lysines acetylated on HDAC1
are conserved [71] .T h eo n l yl y s i n en o tc o n s e r v e di sK 4 3 2
(arginine R433 in HDAC2), which was shown to be the
critical residue for HDAC1 acetylation [70]. The conversion
of R433 of HDAC2 into lysine rendered HDAC2 acetylated
by p300 in vitro although to a lesser extent compared to
HDAC1 [71]. Strikingly, the substitution of the C-terminal
tail of HDAC2 with the tail of HDAC1 determined a full
acetylation of HDAC2, compared to HDAC1 wild type.
Vice versa, HDAC1 bearing the C-terminal tail of HDAC2
was totally refractory to acetylation by p300. Acetylation of
HDAC1 not only reduces the activity of HDAC1 itself, but
acts in trans also on HDAC2 both in vitro and in vivo on
the HDAC1/HDAC2 heterodimers of the Sin3a, NuRD, and
CoREST complexes. These observations clearly show how
single diﬀerences in key residues of HDAC1 and HDAC2
can aﬀect their PTM code. More importantly, they highlight
the crucial role of the C-terminal region in the diﬀerential
regulations of the enzymatic activity of the two enzymes.6 Journal of Biomedicine and Biotechnology
Based on these experimental data, we can speculate that
C-terminal domain of HDAC1 and HDAC2, which is not
conserved in the other, more divergent class I HDAC3 and
HDAC8 [3, 72], has evolved as a molecular platform to
specify and ﬁnely tune the functions of two highly related
proteins in the complex networks of mammalian systems.
Recent work highlights that HDAC2 binds the acetyl-
transferase CBP only in response to cigarette smoke treat-
ment and is, therefore, acetylated. This acetylation relies
on previous CKII-dependent phosphorylation, since the
phosphorylation quadruple mutant is less acetylated after
CS treatment. This is one of the ﬁrst instances of a
crosstalk between diﬀerent PTMs acting on HDAC2 (see
Figure 2). Opposite to what observed for acetylation of
HDAC1 by p300, acetylation of HDAC2 by CBP increases its
transrepressional activity in luciferase-reporter assays [55].
These observations also suggest that the action of diﬀerent
HATs on single HDACs may result in diﬀerent biological
outcomes, creating a multilevel network of regulation.
4.3. Ubiquitination. Ubiquitin (Ub) is a small protein con-
jugated to lysine residues of target substrates through an
isopeptide bond, as a single monomer or as a polyubiqui-
tin chain. The reaction involves a well-deﬁned three-step
enzymatic cascade (E1 activating enzymes, E2 conjugat-
ing enzymes and E3 ubiquitin ligases). Polyubiquitination
mainly targets proteins for degradation via the proteasome
machinery, while monoubiquitination acts as a signal for
diﬀerent biological outputs [36].
Both HDAC1 and HDAC2 have been reported to be
polyubiquitinated in vitro and in vivo [75–77]. HDAC1
is ubiquitinated and rapidly degraded by a proteasome-
dependent mechanism in presence of the antiproliferative
agent quinidine [78]. Gaughan and colleagues were the ﬁrst
to describe a Ub E3 ligase for HDAC1 in vivo [79]. They
showed that HDAC1 is found in complex with the androgen
receptor (AR) protein and the Ub E3 ligase Mdm2 at the
promoter of AR-driven genes upon hormone treatment in
prostate cancer cells. Ubiquitinated forms of HDAC1 were
detected only after hormone treatment and were correlated
to the Ub E3 ligase activity of Mdm2. Mdm2 also ubiq-
uitinates AR protein, and HDAC1 cooperates with Mdm2
possibly through deacetylation of critical lysines of AR
protein and thus reducing transcription of the downstream
gene. HDAC1 ubiquitination by Mdm2 may represent a
further level of ﬁne regulation at the promoter, reducing
HDAC1 protein levels and likely exposing the promoter for
a second round of active transcription.
HDAC1 ubiquitination and proteasome-dependent
degradation was recently shown to have signiﬁcant
biological relevance. Work by Oh and colleagues identiﬁed
a functional interaction between HDAC1 and the Chfr
Ub ligase. Chfr downregulates HDAC1 levels by directly
binding and ubiquitinating HDAC1. This mechanism
correlates with increased invasiveness and metastatic
potential of prostate and breast cancer cell lines [80].
Selective ubiquitination and depletion of HDAC1, but
not of other class I HDACs including HDAC2, is also a
critical step of the proinﬂammation response activated by
t u m o rn e c r o s i sf a c t o r - α (TNFα) through the IKK2 signaling
pathway [81]. Upon binding of TNFα to its receptor, the
IKK complex (IKK1/IKK2/NEMO) phosphorylates the
IkBα protein, which then releases NF-kβ protein. Free
NF-kβ translocates from the cytoplasm to the nucleus
w h e r ei ta c t sa sat r a n s c r i p t i o nf a c t o ra c t i v a t i n gap l e t h o r ao f
inﬂammatory, antiapoptotic and proliferativegenes. HDAC1
is ubiquitinated after TNFα treatment and degraded via the
proteasome machinery, only in the presence of an active
IKK2. As a result, a complete loss of HDAC1 occupancy at
the promoter of p21WAF/CIP1 gene is observed. These results
provide evidence of a link between inﬂammatory signaling
pathways and modulation of chromatin transcription
through PTMs on histone deacetylases.
HDAC2 is speciﬁcally ubiquitinated for proteasomal
degradation by the Ubc8 E2 conjugase and the RLIM E3
ligase upon treatment with valproicacid, aninhibitor of class
I and IIa HDAC enzymatic activities [76].
Interestingly, valproic acid does not aﬀect HDAC1 sta-
bility in endometrial stromal sarcoma cells [82]. This work,
together with the study by Vashisht Gopal and collaborators
[81], suggests the existence of signaling pathways able to
discriminate between HDAC1 and HDAC2 at a PTM level
to achieve diﬀerent speciﬁc responses in diﬀerent cellular
contexts.
Finally, HDAC2 was shown to be phosphorylated and
degraded by the proteasome in bronchial cells upon treat-
ment with cigarette smoke. A possible correlation with the
CKII-dependent phosphorylation was proposed [54]( s e e
Figure 2).
4.4. SUMOylation. The conjugation of SUMO proteins
(SUMO1, SUMO2, and SUMO3) to substrates mirrors
ubiquitin conjugation; an E1-E2-E3 enzymatic cascade adds
SUMO proteins to lysines of target substrates. Diﬀerently
from ubiquitination, the SUMOylation consensus site Φ-K-
X-E (where Φ is an aliphatic residue, preferably L, I or V, K is
lysine, X is any residue and E is glutamate) is frequently, even
though not always, found on substrates [83].
HDAC1 is SUMOylated by SUMO1 in vivo and in vitro,
and by SUMO2/3 in vitro [75, 84, 85]. Two independent
works mapped the SUMOylation sites of HDAC1 on lysines
K444 and K476, but its biological role is still under
investigation. We did not observed an eﬀect of the double
SUMOylation mutant K444R, K476R (2R) on HDAC1
enzymatic activity and transcriptional repression [84], while
work from De Pinho’s laboratory reported a 60% reduction
of transcriptional repression of the 2R HDAC1 mutant, even
if the binding with the Sin3a protein was unaﬀected.
Moreover, overexpression of wild type HDAC1, but not
of the 2R mutant, induced accumulation of cells in the G2
phase of the cell cycle, suggesting that the SUMOylation
mutant of HDAC1 is impaired in some biological func-
tions [75]. Furthermore, other studies have reported that
SUMO modiﬁcation promotes transcriptional repression of
HDAC1/HDAC2 containing complexes, such as Elk1or Mi-
2/NuRD [86, 87].Journal of Biomedicine and Biotechnology 7
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Figure 2: Schematic illustration of the crosstalk between diﬀerent PTMs on HDAC2 in response to oxidative or nitric stress stimuli.
Oxidative ornitric stimulievokea complex response in terms of PTMs onHDAC2 thatresults ina speciﬁc biologicaloutput [54, 55, 73, 74].
Diﬀerent PTMs are illustrated by diﬀerent colors and letters: P (yellow): phosphorylation, A (green): acetylation, U (blue): ubiquitination,
and N (orange): nitrosylation. The modiﬁcation enzymes, when known, are also reported: CKII: casein kinase II, and CBP: CBP histone
acetyltransferase. When a mechanistic relation between two diﬀerent PTMs events is not known, the question mark (?) has been used.
The ability of the 2R HDAC1 mutant to be polyubiq-
uitinated was also evaluated: although both the wild type
and the 2R mutant show consistent ubiquitination, the latter
appeared to be ubiquitinated to a lesser extent [75]. If
this is due to a mutation of the two lysines, which could
serve as target residues for conjugation of ubiquitin, or
to a more complex cross regulation between SUMOylation
and ubiquitination still remains unknown. It is also worth
noticing that SUMOylation of the phospho-null mutant
S421A, S423A of HDAC1 was increased respect to the
wild-type protein [84]. This ﬁnding has not been further
investigated, but it may suggest a negative relationship
between CKII phosphorylation and SUMOylation.
SUMO proteins are reversibly detached from substrates
through the action of SUMO proteases called SENPs
(SENP1–7 in mammals) [88].
HDAC1 can be deSUMOylated in vivo by SENP1 [89], a
SUMO protease able to cleave both conjugated SUMO1 and
SUMO2, but not SUMO3 [90].
HDAC1represses AR-genetranscription [91]andSENP1
was shown to enhance ligand-dependent transcription of
androgen-receptor (AR) driven genes. HDAC1 and HDAC2
were found to complex with SENP1 at the promoter of
AR-genes and the transcription-promoting action of SENP1
is carried out through the deSUMOylation of HDAC1.
Consistent with this model and with previous results [75],
wild type HDAC1 can repress AR-activity up to 90% while
the 2R HDAC1 mutant only to 60% [89].
Up to date, SUMOylation of HDAC2 has not been
reported in the literature, but unpublished data in our
laboratory have identiﬁed lysine 462 as a target site for
SUMOylation of HDAC2 by SUMO1 both in vitro and in
vivo (C.V. Segre’ and S. Chiocca, unpublished data). It is
worth noticing that this SUMO consensus site for HDAC2
is not conserved exactly as in HDAC1, but its position in
the protein sequence is intermediate between the positions
of the two SUMO sites on HDAC1. This might suggest
slight diﬀerences in the regulation of HDAC1 and HDAC2
by SUMOylation.
Proteins can interact with SUMO also in a noncovalent
manner, through a SUMO-Interacting-Motif (SIM) [92].
HDAC2 in particular is recruited by diﬀerent SUMO-bound
transcriptional factors, such as Elk1 and CBP to repress
transcription of target genes [86, 93]. SUMOylation of Elk18 Journal of Biomedicine and Biotechnology
in vitro speciﬁcally promotes HDAC2 binding, suggesting
the presence of a SIM motif on HDAC2. Finally, recent
evidence indicates that HDAC2 promotes SUMOylation
of the translation initiation factor eIF4E, modulating the
translation of a speciﬁc subset of mRNAs [94].
4.5. Nitrosylation. Nitrosylation is a protein modiﬁcation in
which a nitrosyl group (NO) is post-translationally added to
an amino acid residue. Nitric oxide (NO) production in cells
is catalyzed by enzymes called nitric oxide synthases (NOS),
and it represents a key second messenger in a variety of
biological processes including neurotransmission, immune
defense, apoptosis, and cell motility [95]. NO can rapidly
react with the superoxide anion O2
− producing the highly
oxidant specie peroxynitrite (ONOO
−) ,w h i c hi nt u r nr e a c t s
with amino acids and generates a nitrosylated residue.
Tyrosine nitrosylation was observed in HDAC1,HDAC2,
and also HDAC3 in macrophage cells after exposure to
cigarette smoke [96]. Another study using human alve-
olar epithelial cancer cells showed that diﬀerent tyrosine
residues of HDAC2 are nitrosylated after oxidative and nitric
stress: Y68, Y73, Y167, Y146, Y173, and Y253. Interestingly,
mutation of Y253 abolished the proteasomal-dependent
degradation induced by the peroxynitrite generator SIN-1
[73], thus suggesting that tyrosine nitrosylation of HDAC2
is a stress signal to drive speciﬁcally its degradation.
Inneurons,HDAC2iss-nitrosylated oncysteines262and
274 in response to BDNF-NO signaling. Null mutations of
these cysteinesdid notdramatically aﬀectHDAC2enzymatic
activity, but s-nytrosilation caused dissociation of HDAC2
from the promoters of some neuronal speciﬁc genes, such
as Fos, Egr1, Vgf, and Nos1 with concomitant increase of
histone acetylation and transcriptional activation [97]. S-
nitrosylation of HDAC2 also plays a role in the pathogenesis
of Duchenne muscular dystrophy, where it is correlated with
a decrease inHDAC2enzymatic activity and partial rescue of
the myotubediﬀerentiation abilitiesofcells, which are lost in
the pathology [98].
Recent work showed that s-nitrosylation of HDAC2 in
macrophages following lipopolysaccharide (LPS) stimula-
tion aﬀects the stability of the binding between HDAC2 and
MTA1, with consequent dissociation of the NuRD complex
from chromatin and activation of transcription of some
inﬂammatory genes like IL1β,T N F α and MIP2 [99].
This is another indication that PTMs of HDAC1 and
HDAC2 are the ﬁrst and most important level of regulation,
inﬂuencing also other levels of regulation such as multipro-
tein complex formation.
Interestingly, no s-nitrosylation has been reported for
HDAC1 or HDAC3 [98], even if the two cysteines are well
conserved in all three proteins [48].
These studies suggest an emerging role of s-nytrosilation
in regulating the chromatin-associated dynamics of HDAC2,
in a very speciﬁc way also compared to other class I HDACs,
such as the highly related HDAC1.
4.6. Carbonylation. Carbonylation (or alkylation) is a dis-
tinctive PTM of redox signaling pathways occurring in cells
after oxidative stress. Reactive carbonyl species (RCS) derive
from peroxydation of lipids (especially arachidonic acid),
which generate α-β-unsatured aldehydes (e.g., 4-hydroxy-2-
nonenal) and α-β-unsatured ketones (e.g., cyclopentenone
prostaglandis). Covalent binding of RCS on cysteinyl thiols
of substrate proteins is termed carbonylation [74].
HDAC1, HDAC2, and HDAC3, but not the other class
I HDAC8, are carbonylated after treatment with cyclopen-
tenone prostaglandis [100]. The cysteines involved in this
PTM have been identiﬁed for HDAC1 as Cys 261 and Cys
273, which are conserved in both HDAC2 and HDAC3, but
not in HDAC8, which in fact is not modiﬁed. Carbonylation
of HDAC1 does not impair its intrinsic enzymatic activity,
but disrupts its interactions with binding partners and
histone substrates in vivo. As a consequence, increased
acetylation of lysine 9 of histone H3 was observed with
concomitant induction of transcription of some HDAC1-
repressed genes, such as HO-1, Gadd45, and HSP70. This
paper represents one of the ﬁrst reports linking redox
signaling species such as RCS to modiﬁcation in chromatin
states through a direct modulation of histone deacteylases,
resulting in the expression of genes involved in the response
of cells to oxidative stresses.
The authors did not formally demonstrate that the
corresponding cysteines of HDAC2 and HDAC3 are the
carbonylation sites as for HDAC1, but speculated that they
are likely to be the target residues of the cyclopentenone
prostaglandis covalent binding, based on the evolutionary
conservation with HDAC1. It is a reasonable speculation
considering that for other PTMs, such as phosphorylation,
a similar pattern of modiﬁcation occurs on corresponding
residues of HDAC1 and HDAC2 (see Table 1 and Figure 1).
Nevertheless, in the case of redoxsignaling-associated PTMs,
the picture might be more complicated. In fact, HDAC2 is
modiﬁed by NO on the conserved Cys 262 and Cys 274 [97],
but HDAC1 and HDAC3 are not [98], indicating that the
simple conservation of the same amino acidic stretch is not
always suﬃcient to have the same PTM. It is likely that other
factors, such as cell-type speciﬁc interactors, contribute to
the ﬁnal PTM pattern of single HDACs.
5.Reassemblingthe Piecesofthe Puzzle:
The Integrationof theCode
The bulk of work on HDAC1 and HDAC2 PTMs (summa-
rized in Table 1) seems to unveil a complex “code” by which
t h et w op r o t e i n sc a nb ed i ﬀerentially regulated, despite their
high overall similarity and partially redundant roles.
Two “modular” areas of PTMs can be distinguished
on HDAC1 and HDAC2: a “tyrosine-cysteine modiﬁca-
tion” central domain and a “serine-lysine modiﬁcation” C-
terminal domain (see Figures 1(a) and 1(b)).
The vast majority of the modiﬁcations reported in the
central domain of the two HDACs are nitrosylations and
carbonylations in consequence of inﬂammatory/oxidative
stresses; itcouldbespeculatedthatthecentraldomainsofthe
deacetylases act as a platform for the integration of signals in
response to stress stimuli (such as cigarette smoke, LPS, orJournal of Biomedicine and Biotechnology 9
Table 1: Summary of the PTM code on HDAC1 and HDAC2. The modiﬁcation/demodiﬁcationenzymes, amino acidic sites, and the eﬀects
and/or the biological relevance caused by the modiﬁcation and the citations (refs) are reported.
Phosphorylation
Kinase/
Phosphatase Sites Eﬀects/biological relevance Refs
HDAC1
CKII S421, S423 in vivo and in
vitro Stimulationof catalytic activity and binding properties [45, 48, 49]
PKA in vitro n.r. [45]
PKC, Cdc2 and
MAP kinase
NOT phosphorylated in
vitro /[ 45]
n.r S406 in vivo Consequent to viral infection [56, 57]
n.r. S393 identiﬁed by mass spectrometry analysis [45, 46, 51]
n.r. Y221 identiﬁed by mass spectrometry analysis [46]
Protein
phosphatase 1 in vitro n.r. [62]
λ-phosphatase in vitro n.r. [62]
HDAC2
CKII S394, S422, S424 in vivo
and in vitro
Stimulationof catalytic activity and binding properties [50]
Diﬀerential localization on chromatin [47, 52]
Transcriptional regulation of SM22 α in vascular cells [53]
Transcriptional regulation in bronchial cells [54, 55]
PKA, PKC, and
PKG
NOT phosphorylated in
vitro /[ 50]
n.r. S411 in vivo n.r. [50]
n.r. S407 in vivo Consequent to viral infection [56–58]
Protein
phosphatase 1 in vitro n.r. [62]
λ-phosphatase in vitro n.r. [62]
Acetylation
HAT/HDAC Sites Eﬀects/biological relevance Refs
HDAC1 p300 (HAT) K218, K220, K432, K438,
K439, K441 Transcriptional attenuation of GR-driven genes [70]
p300 (HAT) in vivo and in vitro Reduction of catalytic activity and binding properties [71]
HDAC2 CBP (HAT) n.r. Increase of transcriptional repressive activity [55]
p300 (HAT) NOT acetylated / [71]
Ubiquitination
E1/E2/E3 Sites Eﬀects/biological relevance Refs
HDAC1
Mdm2 E3 ligase n.r. Modulation of transcription at AR-driven promoters [79]
Chfr E3 ligase n.r. Increase of invasiveness and metastatic potential of
cancer cells [80]
n.r. n.r. Response to the antiproliferative agent quinidine [78]
n.r. n.r. Response to TNF α stimulation via IKK2 signalling [81]
HDAC2
Ubc8 E2
conjugase n.r. Response to valproic acid treatment [76]
RLIM E3 ligase n.r.
n.r. n.r. Response to oxidative and nitric stress [54, 73]
SUMOylation
SUMO
protein/proteases Sites Eﬀects/biological relevance Refs
HDAC1
SUMO1 K444, K476 in vivo and in
vitro Promotionof transcriptional repression [70][ 71, 81]
SUMO2/3 in vitro n.r. [82]
SENP1 SUMO1/2
protease n.r. Enhancement of transcription at AR-driven genes [86]10 Journal of Biomedicine and Biotechnology
Table 1: Continued.
Phosphorylation
Kinase/
Phosphatase Sites Eﬀects/biological relevance Refs
HDAC2 SUMO1 K462 in vivo and in vitro n.r.
unpublished
data
( C .V .S e g r e ’a n d
S. Chiocca)
Nitrosylation
Enzyme Sites Eﬀects/biological relevance Refs
HDAC1 n.r. Tyrosine(s) Response to cigarette smokein macrophages [96]
n.r. NOT s-nitrosylated / [98]
HDAC2
n.r. Tyrosine(s) Response to cigarette smokein macrophages [96]
n.r. Y68, Y73, Y167, Y146,
Y173, Y253
Response to oxidative and nitric stress in bronchial cells [73]
Signalfor proteasomal degradation (Y253)
n.r. C262, C274
(s-nitrosylation)
Response to BDNF-NO signalling in neurons [97]
Promotionof dissociation from Fos, Egr1, Vgf, and
Nos1 promoters
n.r. s-nitrosylation
Partial rescue of myotube diﬀerentiation in Duchenne’s
cells [98]
Decrease of the enzymatic activity
n.r. s-nitrosylation Dissociation of the NuRD complex [99]
Activation of L1β,T N Fα, and MIP2 genes in
macrophages
Carbonylation
Enzyme Sites Eﬀects/biological relevance Refs
HDAC1 n.r. C261, C273
Disruption of binding with transcriptional partners
and histone substrates [100]
Transcriptional derepression of the HO-1, Gadd45, and
HSP70 genes
HDAC2 n.r. carbonylated n.r. [100]
S: serine, Y: tyrosine, K: lysine, C: cysteine, n.r.: not reported in literature or not investigated, HAT: histone acetyltransferase, HDAC: histone deacetylase,
E1/E2/E3: ubiquitin enzymatic cascade (see text).
RCS-inducedinﬂammation)ortopeculiarsignalingpathway
(such as the BDNF-NO axis). On the other hand, a broader
spectrum of PTMs occurs on the C-terminal domains in
response to a variety of diﬀerent signaling pathways (such
as hypoxia, hormone stimulation, extracellular signaling).
This modular organization highlights the potential of this
post-translational code for the modulation of HDAC1 and
HDAC2 functions in many cellular pathways or biological
responses to diﬀerent stimuli.
As it was described in this paper, a broad number of
single PTMs occur on HDAC1 and HDAC2 but strikingly
very few examples of the interplay among them have been
reported so far. The only reported example of PTM crosstalk
occurs on HDAC2 in human bronchial epithelial cells when
injured with cigarette smoke (CS) [55], (see Figure 2). In
response to CS, HDAC2 associates with CKII, which in
turn induces a strong phosphorylation of HDAC2 itself. CS
also induces the formation of a complex between HDAC2
and the acetyltransferase CBP with consequent HDAC2
acetylation and increase in its transcriptional repressive
activity. An HDAC2 quadruple mutant for all the CKII-
dependent sites is far less acetylated than the wild type
in response to CS, showing that acetylation of HDAC2
relies on its CKII phosphorylation. Previous work from
the same group [54] had also reported CKII dependent
degradation of HDAC2 after CS exposure, and a global
model was proposed. Cigarette smoke induces a bulk of
phosphorylation of HDAC2, which determines its associa-
tion with repressor partners and enhances its acetylation via
CBP, contributing to further increase its repressive activities.
On the other hand, CS-induced phosphorylation induces
ubiquitination and degradation of HDAC2; reduction levels
of HDAC2 are associated with steroid resistance in COPD
and asthma [101], suggesting a mechanistic explanation for
this resistance in smoker patients. It will be interesting in the
futuretoverifywhich genesarerepressed inbronchialcellsin
response to CS-induced phosphoacetylation of HDAC2 and
if acetylation is linked to ubiquitination, or if they are two
distinct parallel pathways driven by CKII phosphorylation.
Finally,oxidativeand nitric stress inducenitrosylation on
tyrosine 253 of HDAC2 in bronchial cells, which represents a
signal for its proteasomal degradation [73]. Its possible link
with CS-induced-CKII-phosphorylation and degradation
has not been investigated. Nevertheless, it is clear thatJournal of Biomedicine and Biotechnology 11
cigarette smoke (and similar stress stimuli) evokesa complex
PTM response on HDAC2, in which both the modular
modiﬁcation domains, the central and the C-terminal ones,
are involved and cross interact. It is a step forward in the
elucidation of the PTM code, but more investigation is still
required to unveil the global panorama.
Another possible interplay between PTMs involves
SUMOylation and CKII-phosphorylation of HDAC1. We
haveobserved that the CKIIphosphorylation mutant S421A,
S423A is more widely SUMOylated than the wild-type
HDAC1[84]. This suggestsa negative regulation ofSUMOy-
lation by the action of CKII, possibly as a consequence of
the lost catalytic activity and binding properties of HDAC1
S421A and S423A, but the molecular mechanisms and the
physiological role have not been investigated.
Finally, it was shown by two independent groups that
ubiquitinated [79] and SUMOylated [89] forms of HDAC1
can be found at promoters of AR-driven genes and that
both these modiﬁcations of HDAC1 contribute to the
ﬁne modulation of transcription. It will be challenging
to investigate whether a crosstalk between SUMOylation
and ubiquitination of HDAC1 exists at androgen-responsive
promoters and to which extent this interplay aﬀects gene
transcription.
6.Conclusion:Why DecipheringtheCode?
Class I histone deacetylases, and HDAC1 and HDAC2 in
particular, have broad expression in many tissues and play
a crucial role in cell cycle progression and proliferation
[20]. HDAC1 and HDAC2 are deregulated in many cancers
and are emerging as the main deacetylases involved in
aberrant pathways of tumor cells in humans. Overexpression
of HDAC1 is reported for gastric [102, 103], pancreatic [104,
105], colorectal [106], hepatocellular [107], and prostatic
[108] carcinomas. HDAC2 plays a major role in APC-colon
cancer;itsoverexpression ispresent already attheearly polyp
stage [109]. High levels of HDAC2 are found also in cervical
dysplasia and invasive carcinomas [105]. High expression
levels of both HDAC1 and HDAC2, together with HDAC3,
have been associated with advanced stages of disease in
prostate, gastric and colorectal cancers [105, 106].
Given the involvement of deacetylases in cancers,
inhibitors of HDACs (HDACi) have been looked at as
promising anticancer drugs and several classes of HDACi
display potent anticancer activities in vitro.H D A C ia ﬀect
tumor cell growth and survival through induction of cell
cycle arrest, block of angiogenesis, increase of antigenicity
of tumor cells and induction of apoptosis [110]. A large
number of clinical trials using diﬀerent HDACi have shown
their promising antitumor response in vivo; two of them
have been approved by US FDA for the treatment of
T-cell cutaneous lymphoma; suberoylanilide hydroxamic
acid (SAHA, brand name vorinostat) in 2006 [111]a n d
romidepsin (brand name istodax) in 2009 [112].
Unfortunately, their use is still restricted to speciﬁc types
of cancer and adverse side eﬀects have also been recorded,
in particular to the blood system [113]. One of the main
reasons may be the fact that HDACi are not HDAC-isoform
speciﬁc and this, given the diﬀerentiation of roles of single
HDACsindiﬀerentnormal andcancertissues,may represent
a considerable limitation to their use in clinical settings.
HDAC1 and HDAC2 are not only relevant in cancer
etiology, but are also important in other human diseases.
An abnormal transcriptional repression of the growth factor
BDNF by HDAC1/HDAC2containing complexes is found in
cortical neurons expressing the mutant huntingtin protein
typical of the neurodegenerative Huntington disease [114].
HDAC2 was recently shown to be a crucial regulator of
aberrant genetic programs in renal ﬁbrosis associated with
diabetes [115]. Finally, HDAC2 is involved in lung diseases
such as COPD (as discussed above) and asthma [116].
It is clear that the integration of all the PTMs in a
coherent and global code is a priority for understanding
the regulatory networks operating on these key enzymes in
diﬀerentcellular,developmental,physiologic,andpathologic
phenomena, with relevant clinical implications for a variety
of human diseases.
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